Pfizer has granted exclusive development and marketing rights for its DPP(1)-IVi compound, PF-00734200, to SatRx, a ChemRar group company. SatRX is developing PF-00734200 for type 2 diabetes.
 
Pfizer granted exclusive worldwide rights (outside China) for development and commercialization of PF-00734200 as monotherapy or in combination with other drugs. Pfizer will receive royalties and milestone payments based on commercialization activities.
 
Yulia Baybikova, general manager of SatRx, commented, “This licensing agreement with Pfizer provides SatRx with essential background for development of fully innovative tools to tune the metabolism of patients with type 2 diabetes and obesity. Synergistic actions of DPP-IVi and proprietary new SatRx molecules active in the incretin metabolic cascade will provide significant therapeutic benefits and promises to increase patient compliance and quality of life.”